Every minute matters after acute ischemic stroke (AIS) onset in the path to recovery. Early treatment is essential for both IV-Thrombolysis (IVT) and mechanical thrombectomy (MT). Recent research has explored extending the standard treatment window by using advanced imaging selection when administering IVT or MT. Many questions remain about whether IV thrombolysis or interventional mechanical thrombectomy is better suited for the treatment of AIS.
Join three thought leaders in the fields as they provide an overview of pharmacological and mechanical avenues to recanalization. They will discuss recently published trials, major advances in MT and IVT over the last five years, combination of IVT and MT, especially in patients transferred from other hospitals, and the potential utility of thrombectomy and treatment approach for distal occlusions.
From the standpoint of clinical trial operations, the speakers will also discuss thrombolytic treatment options as they relate to the infrastructure of stroke centers and their capacity, given that even many developed countries have been affected by a lack of critical care beds with the COVID-19 pandemic, and similarly may not be prepared to offer novel stroke treatments to all patients affected. Patient referral and recruitment is another topic of interest as researchers consider the pros and cons of broadening study eligibility by widening the time window for thrombolysis, which may make a difference for people in underserved regions of the world.
Register today to learn be a part of this educational webinar to learn more about thrombolytic therapies and the potential for complementary approaches to treat patients with stroke.
Dileep R. Yavagal, MD, FAHA, FAAN, FSVIN, Clinical Professor of Neurology and Neurosurgery at the University of Miami of Medicine
Dr. Dileep R. Yavagal is the director of Interventional Neurology and co-director of Neuroendovascular Surgery at the University of Miami & Jackson Memorial Hospitals and clinical professor of Neurology and Neurosurgery at the University of Miami of Medicine. He completed his MBBS and MD in Internal Medicine at Seth G. S. Medical & King Edward Memorial Hospitals in Mumbai, India followed by a Neurology residency at Harvard at Massachusetts General & Brigham and Women’s Hospitals. His focus on the then new field of interventional neurology led him to pursue fellowships in Neurocritical Care and Interventional Neuroradiology Fellowships at Columbia Presbyterian in NYC and UCLA respectively. He has been at the University of Miami since 2008. Dr. Yavagal co-led the first randomized controlled trial of intra-arterial delivery of stem cells in ischemic stroke: RECOVER Stroke.Message Presenter
Werner Hacke, MD, PhD, DSc, FAHA, FESC, Senior Professor of Medicine at the Ruprecht- Karls University in Heidelberg
Professor Werner Hacke holds degrees in both Medicine and Psychology. He is a board-certified neurologist and Critical Care specialist. He received his Neurology training at the RWTH in Aachen, Germany and at the University of Berne, Switzerland. He was professor and chair for 27 years until September 2014 and is now the first and only senior professor of Medicine at the Ruprecht- Karls University in Heidelberg. He was the founding president of the European Stroke Organization (ESO) and vice president of the World Federation of Neurology (WFN) and most recently the president of the World Stroke Organization (WSO).Message Presenter
Francisco J. Martinez-Torres, MD, PhD, Senior Medical Director, Neuroscience, Global Clinical Development
Dr. Francisco J. Martinez-Torres has a clinical background in Internal Medicine, Critical Care Medicine and Neurology (Stroke) as well as extensive basic, translational and clinical research experience in Neuroscience, Immunology and HIV in academia and industry. His pharmaceutical development expertise encompasses clinical programs phases I to III, across diverse therapeutic platforms (e.g., small molecules, biologicals, gene therapy) in the Neuroscience and Rare Disease spaces. Dr. Martinez-Torres worked as a clinical and research fellow in the Department of Neurology at the University of Heidelberg from 2001-2007, where he served as a physician in the stroke unit and conducted translational and clinical research projects in herpes simplex encephalitis (HSE), stroke, and multiple sclerosis (MS).Message Presenter
Who Should Attend?
- Directors of Neurology Programs
- Clinical Trial Managers/Directors/VPs
What You Will Learn
- The history of recanalization strategies and current treatment guidelines
- Recent research examining the utility of pharmacological interventions
- The potential for complementary approaches with mechanical and pharmacological recanalization
- Strategies for optimizing study design and enhancing patient recruitment
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.
Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.